Published Date: 16 Feb 2023
Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.
Read Full NewsA randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.
A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation